Glaxo Sued in the U.K. Over Avandia Diabetes Drug Health Risks

GlaxoSmithKline Plc (GSK) faces at least four U.K. lawsuits over its Avandia diabetes drug amid claims it’s linked to an increased risk of heart attacks and congestive heart failure.

The potential number of claims against the U.K.’s biggest drugmaker may increase, said Daniel Slade, a lawyer at Manchester firm Express Solicitors, who represents consumers in the four suits and has a further 15 clients.

“We expect the number of claims to increase as there are potentially thousands of people out there who took Avandia in the U.K.,” Slade said in a telephone interview today. “Hopefully these claims will lead to more careful studies and checks on drugs that are widely marketed.”

Glaxo has said it paid more than $3 billion to settle U.S. federal and state government claims that it illegally marketed Avandia, once the world’s best-selling diabetes pill, and other medications.

David Daley, a spokesman for Brentford, U.K.-based Glaxo, said that while the company can’t comment on specific cases, it has “every sympathy for people with health complications associated with diabetes.”

“We continue to believe that the company acted appropriately and responsibly in its management of Avandia,” Daley said.

Glaxo indicated to Express Solicitors that it intends to fight the claims, filed in Manchester, England, setting aside 600,000 pounds ($946,200) in litigation costs for one case, Slade said.

“Even though a settlement was reached in the U.S. to settle lawsuits, it seems GSK wishes to put up a fight in the U.K.,” Slade said.

Editors: Anthony Aarons, Christopher Scinta

To contact the reporter on this story: Jeremy Hodges in London at jhodges17@bloomberg.net

To contact the editor responsible for this story: Anthony Aarons at aaarons@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.